OpenEvidence Disrupts UpToDate

OpenEvidence is disrupting UpToDate by changing the buying unit from hospitals to individual doctors. UpToDate sells a curated reference library through institutional contracts, often around $500 per seat, while OpenEvidence gives doctors a free AI search tool with journal access, citations, and no patient record connection, which let it spread doctor by doctor without the usual long hospital sales cycle and build massive usage before moving upmarket.1 2 3 4

• The product difference is concrete. UpToDate is a library of expert written summaries that a clinician reads through. OpenEvidence lets a doctor type a messy case question, get a synthesized answer, and click through to supporting literature, which better matches point of care behavior when time is tight.2 4
• The business model difference is just as important. UpToDate monetizes through institution paid subscriptions, while OpenEvidence monetizes physician attention with pharma and med device ads at $70 to $150+ CPM, which means free access can still become meaningful revenue at scale.2 4
• This wedge gave OpenEvidence speed. It reached $50M annualized revenue in June 2025, later $150M by November 2025 and $300M by July 2026, while UpToDate was roughly $595M in 2025 era revenue and then about $690M in 2025 revenue, still much larger but growing far more slowly through enterprise channels.1 2 3 4

The next phase is not just search replacing search. The market is moving toward an all in one doctor assistant that combines research, note taking, calling, billing support, and prescribing inside the clinical workflow. If OpenEvidence keeps turning free physician usage into in workflow enterprise software, it can pull UpToDate from a reference budget into a much broader clinical operating layer.1 3 4